Research demonstrates controlled release of triacetyluridine in polymeric nanomaterials, suggesting enhanced therapeutic potential for brain delivery.
Triacetyluridine (TAU) has higher oral bioavailability and represents a novel mechanism for delivering exogenous pyrimidines to the brain. It is commonly employed to mitigate the adverse effects of chemotherapy, attenuate toxicity, enhance the effectiveness of anticancer treatment, boost cognitive functions and memory, and provide therapeutic support for neurological and hereditary disorders. p(HEMA‐MAC) was synthesized using non‐surfactant emulsion polymerization. Then, they were modified for TAU specificity by using immobilized metal ion (Cu +’ ) affinity and characterized. Optimization of TAU adsorption conditions and controlled release studies of TAU were performed. At physiological Ph = 7.4, approximately 45.8% of 2 mg/mL TAU‐loaded nanopolymers were shown to be controlled, efficient release within 90 min.
No takes yet. Share an insight, caveat, or question.
Kuru et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: